Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells
Figure 1
Antiproliferative effects of γ-tocotrienol, PPARγ agonists (rosiglitazone and troglitazone), and PPARγ antagonists (GW9662 and T0070907) on (a) MCF-7 and (b) MDA-MB-231 human breast cancer cells. MCF-7 cells were plated at a density of (6 wells per group) in 24-well culture plates and exposed to treatment media for a 4-day period. Afterwards viable cell number was determined using MTT colorimetric assay. MDA-MB-231 cells were plated at a density of (6 wells per group) in 96-well culture plates and exposed to treatment media for a 4-day period. Afterwards viable cell number was determined using MTT colorimetric assay. Vertical bars indicate mean cell count ± SEM in each treatment group. as compared with vehicle-treated controls.
